The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Codiak BioSciences (NASDAQ: CDAK ) stock is falling hard on Monday after the company announced plans for an asset sale through a Chapter 11 bankruptcy. According to a press release, Codiak BioSciences...
Codiak BioSciences Inc. CDAK, -4.56% said Monday that it has field for bankruptcy, and it looking to selloff of its assets to maximize the company's value. “The Board and management team have thorou...
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s...
– Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting –...
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 61.54% and 701.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stoc...
Codiak BioSciences Inc (NASDAQ: CDAK) announced platform-validating clinical data from Phase 1 trials of exoSTING and exoIL-12, and it plans to advance both candidates into Phase 2 trials. In an ...
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 55% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...
After losing some value lately, a hammer chart pattern has been formed for Codiak BioSciences, Inc. (CDAK), indicating that the stock has found support. This, combined with an upward trend in earnings...
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy....